Ryan Murray, MD
Family Medicine · Winston Salem, NCNPI 1932333952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 52.1% of the total. Reporting peaked in 2019 at $405 and has fallen 96.1% since, to $16 in 2025.
Across 77 payments — averaging $13.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$562
- Amgen$93
- AstraZeneca$67
- Johnson & Johnson$66
- Lilly USA, LLC$66
- Boehringer Ingelheim$53
- plus $170 from 7 others
Across 69 payments — averaging $1914.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$132K
What the payments were for
- Food & beverage$1,04597%
- Education$323%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $562 |
| Amgen | 6 | $93 |
| AstraZeneca | 5 | $67 |
| Johnson & Johnson | 5 | $66 |
| Lilly USA, LLC | 4 | $66 |
| Boehringer Ingelheim | 3 | $53 |
| Mannkind Corporation | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| AbbVie(2 entities) | 2 | $29 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,077 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $118,217 |
| JardianceEmpagliflozin | 31 | $52,845 |
| EliquisApixaban | 43 | $49,119 |
| FarxigaDapagliflozin Propanediol | 32 | $28,124 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $26,088 |
| TrulicityDulaglutide | 22 | $23,803 |
| Tresiba Flextouch U-100Insulin Degludec | 46 | $15,923 |
| LotrelAmlodipine Besylate/Benazepril | 12 | $4,311 |
| Rosuvastatin Calcium | 193 | $3,247 |
| Levothyroxine Sodium | 198 | $2,810 |
| SynthroidLevothyroxine Sodium | 33 | $2,806 |
| Gabapentin | 139 | $2,651 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 27 | $2,469 |
| Atorvastatin Calcium | 239 | $2,464 |
| Omeprazole | 135 | $2,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $562 | $118,21750 claims |
| Boehringer IngelheimJardiance | $53 | $52,84531 claims |
| AstraZenecaFarxiga | $67 | $28,12432 claims |
| Lilly USA, LLCTrulicity | $66 | $23,80322 claims |
| AbbVieSynthroid | $29 | $2,80633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Winston Salem
- David DundeeWinston Salem$633K
- Cressent PresslyWinston Salem$199K
- Lucian VladWinston Salem$46K
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.